Funding sources: None
Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
Version of Record online: 5 JUN 2014
© 2014 The International Society of Dermatology
International Journal of Dermatology
Volume 53, Issue 11, pages 1351–1357, November 2014
How to Cite
Jung, J. Y., Yeon, J. H., Choi, J. W., Kwon, S. H., Kim, B. J., Youn, S. W., Park, K. C. and Huh, C. H. (2014), Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. International Journal of Dermatology, 53: 1351–1357. doi: 10.1111/ijd.12060
Conflicts of interest: The authors state no conflict of interest.
- Issue online: 20 OCT 2014
- Version of Record online: 5 JUN 2014
Finasteride at a dose of 1 mg/d has been reported to show no significant improvement in 30–50% of patients with androgenetic alopecia (AGA). Dutasteride, a dual inhibitor of both type I and type II 5 alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, which is the key contributor of AGA.
Materials and methods
Our aim is to evaluate clinical efficacy and tolerability of dutasteride in men with AGA who do not show clinical improvement to the conventional finasteride treatment. A total of 35 Korean men with AGA who had not shown significant clinical improvement when treated with finasteride 1 mg/d for at least six months received dutasteride at a dose of 0.5 mg/d for six months. Efficacy was evaluated by global photograph assessment and phototrichogram. Safety assessment was performed through physical examination and adverse event report.
Of the 31 patients who completed the treatment, 24 patients (77.4%) were improved by the global photography (17 were slightly, six moderately, and one markedly improved) compared with the post-finasteride treatment. There was no significant change in seven patients (22.6%), and aggravation was not reported. Hair density and thickness significantly increased by 10.3% (87 ± 12–96 ± 12/cm2) and 18.9% (0.053 ± 0.012–0.063 ± 0.011 mm), respectively, in phototrichogram assessment. Side effects included transient sexual dysfunction in six patients (17.1%).
Dutasteride is suggestive to be an alternative treatment option to patients with AGA who do not clinically respond to finasteride in six months.